Editas insider sale: Amy Parison sells 679 shares under automatic plan at $2.58

Rhea-AI Filing Summary

Editas Medicine insider transaction by SVP & Chief Financial Officer Amy Parison: The filing reports a non-discretionary sale of 679 shares of common stock at $2.58 per share, executed under a durable automatic sales instruction plan. The sale satisfied tax withholding obligations arising from the vesting of restricted stock units and is explicitly described as not a discretionary trade by the reporting person.

After the reported sale the reporting person beneficially owned 16,827 shares directly. The filing identifies the issuer as Editas Medicine, Inc. and classifies the report as a Form 4 statement of changes in beneficial ownership.

Positive

• Sale executed under a pre-established automatic sales instruction plan, indicating it was not a discretionary trade
• Transaction purpose explicitly disclosed as covering tax withholding from RSU vesting
• Post-transaction beneficial ownership disclosed (16,827 shares), improving transparency

Negative

• Reduction in direct holdings of 679 shares following the sale
• Sale price reported at $2.58 per share, reflecting the price realized on the disposition

Insights

Financial Analyst

TL;DR: Routine, non-discretionary sale to cover taxes; small, likely immaterial change to holdings.

The transaction is clearly documented as a sale under an automatic instruction plan to cover tax withholding from RSU vesting. The economics are transparent: 679 shares sold at $2.58 each. This type of sale typically signals no active trading decision by the officer and therefore lacks fresh informational content about company prospects. From a market-impact standpoint, the size of the sale is small relative to typical public float and is unlikely to affect valuation.

Corporate Governance Expert

TL;DR: Proper use of pre-established plan and explicit disclosure reduces governance concerns.

The reporting person discloses that the sale was effected pursuant to a durable automatic sales instruction plan adopted in 2022 and was executed to satisfy tax withholding on vested RSUs. Stating that the sale was not discretionary and providing the plan context adheres to best practices for insider transaction transparency. The Form 4 presentation is complete for the reported non-derivative transaction and includes post-transaction beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S(1)		679	D	$2.58	16,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 6, 2025. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Amy Parison	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Editas (EDIT) report for Amy Parison?

The Form 4 reports a sale of 679 shares of Editas common stock by Amy Parison, the SVP and Chief Financial Officer.

Why were the 679 shares sold according to the filing?

The filing states the sale was effected to meet tax withholding obligations arising from the vesting of restricted stock units.

Was the sale a discretionary trade or part of a plan?

The sale was made pursuant to a durable automatic sales instruction plan adopted by the reporting person and is described as not a discretionary trade.

At what price were the shares sold and what are holdings after the sale?

The shares were sold at $2.58 per share, and the reporting person beneficially owned 16,827 shares after the transaction.

Does the Form 4 indicate any derivative transactions by the reporting person?

No. The Form 4 lists only a non-derivative common stock sale and contains no entries in the derivatives table.